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Species-specific pathogenicity of severe fever with thrombocytopenia syndrome virus is 1 
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Severe fever with thrombocytopenia syndrome virus (SFTSV) is a novel 22 
emerging virus that has been identified in China, South Korea, and Japan, and induces 23 
thrombocytopenia and leukocytopenia in humans with a high case fatality rate. SFTSV 24 
is pathogenic to humans, while immunocompetent adult mice and golden Syrian 25 
hamsters infected with SFTSV never show apparent symptoms. However, mice 26 
deficient for the gene encoding the chain of the interferon (IFN)  and  receptor 27 
(Ifnar1
-/-
 mice) and golden Syrian hamsters deficient for the gene encoding signal 28 
transducer and activator of transcription 2 (Stat2
-/-
 hamsters) are highly susceptible to 29 
SFTSV infection, with infection resulting in death. The nonstructural protein (NSs) of 30 
SFTSV has been reported to inhibit the type I IFN response through sequestration of 31 
human STAT proteins. Here, we demonstrated that SFTSV induces lethal acute disease 32 
in STAT2-deficient mice, but not in STAT1-deficient mice. Furthermore, we discovered 33 
that NSs cannot inhibit type I IFN signaling in murine cells due to an inability to bind to 34 
murine STAT2. Taken together, our results imply that the dysfunction of NSs in 35 
antagonizing murine STAT2 can lead to inefficient replication and the loss of 36 





Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious 40 
disease caused by SFTS virus (SFTSV), which has been reported in China, South Korea, 41 
and Japan. Here, we revealed that mice lacking STAT2, which is an important factor for 42 
antiviral innate immunity, are highly susceptible to SFTSV infection. We also show that 43 
SFTSV NSs cannot exert its anti-innate immunity activity in mice due to the inability of 44 
the protein to bind to murine STAT2. Our findings suggest that the dysfunction of 45 
SFTSV NSs as an IFN antagonist in murine cells confers a loss of pathogenicity of 46 
SFTSV in mice. 47 
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Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious 52 
disease caused by the SFTS virus (SFTSV), which is a novel Phlebovirus of the 53 
Phenuiviridae family. SFTSV was first isolated in rural areas of central China in 2011 54 
and subsequently identified in South Korea and Japan (1-4). Moreover, another 55 
emerging phlebovirus genetically close to SFTSV, Hartland virus, was found in the 56 
United States (5). SFTS is clinically characterized by fever, vomiting, diarrhea, 57 
thrombocytopenia, leukocytopenia, and elevated serum levels of enzymes, such as 58 
creatine kinase (CK), aspartate aminotransferase (AST), alanine transaminase (ALT), 59 
and lactate dehydrogenase (LDH) (6-8). However, the pathogenesis of SFTSV in 60 
humans is still poorly understood, and no effective vaccines or antiviral drugs are 61 
currently available for treatment of SFTS. 62 
The SFTSV genome is composed of three negative-strand RNA segments (S, M, 63 
and L). The L segment encodes the viral RNA-dependent RNA polymerase (L), the M 64 
segment encodes the glycoprotein precursors (Gn and Gc), and the S segment encodes 65 
the nucleocapsid protein (N) and nonstructural protein (NSs).  66 
The innate immune response, including the type I interferon (IFN) response, is 67 
important for preventing viral infection (9). Antiviral innate immunity is initiated by the 68 
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recognition of viral infection through cellular pattern recognition receptors (PRRs), such 69 
as transmembrane toll-like receptor 3 (TLR3), cytosolic RIG-I-like receptors, and 70 
MDA5 (10). Upon recognition, this signal cascade leads to the induction of type I IFN. 71 
The activation of the IFN signaling pathway by the binding of secreted IFN to IFN 72 
receptors results in the phosphorylation of STAT1 and STAT2. The heterodimer or 73 
homodimer of phosphorylated STAT forms heterotrimeric interferon-stimulated gene 74 
factor 3 (ISGF3) with IRF-9. The translocation of ISGF3 into the cell nucleus results in 75 
the activation of antiviral IFN-stimulated genes (ISGs) by its binding to an 76 
IFN-stimulated response element (ISRE) (11). However, during a phlebovirus infection, 77 
viral NSs is thought to play a major role in repressing the innate immune response by 78 
targeting the IFN response pathway as an IFN antagonist (12-15). Previous studies have 79 
reported that NSs of SFTSV inhibits type I and III IFN responses through sequestration 80 
of human STAT2 protein in viral replication complexes (13-15). 81 
SFTSV infections do not cause severe disease in immunocompetent mice and 82 
golden Syrian hamsters, while type I IFN receptor knock-out (Ifnar1
-/-
) mice, which 83 
lack the gene encoding the  chain of the IFN  and  receptor, and STAT2-deficient 84 
golden Syrian hamsters are highly susceptible to SFTSV, with infection resulting in 85 
death (16-19). This suggests that efficient replication of SFTSV in mice and hamsters is 86 
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prevented by antiviral innate immunity and that NSs of SFTSV does not inhibit IFN 87 
signaling in murine and hamster cells. STAT1 and STAT2 are important factors for 88 
antiviral innate immunity. However, the relationship between SFTSV pathogenicity and 89 
STAT function remains unknown. In this study, to investigate the role of STAT1 and 90 
STAT2 in the pathogenesis and replication of SFTSV in mice, we examined the 91 




 mice and measured the antagonistic 92 
activities of NSs against IFN signaling in murine cells.  93 




SFTSV infection to Ifnar1
-/-
 mice. 96 
It has been reported that Ifnar1
-/-
 mice are highly susceptible to SFTSV strains 97 
YL-1 and SPL010, with infection resulting in death (16-17). In this study, we used the 98 
YG-1 strain isolated from the first SFTS patient reported in Japan (4). Wild-type 99 
C57BL/6 mice and Ifnar1
-/-
 mice were intradermally (id) inoculated with 10 focus 100 
forming units (FFU) of the SFTSV (YG-1). All infected wild-type mice survived 101 
without any clinical signs (Fig. 1A). In contrast, all infected Ifnar1
-/-
 mice died 5 to 8 102 
days after infection (Fig. 1A). Moreover, all Ifnar1
-/-
 mice infected with SFTSV showed 103 
severe body weight loss, leukocytopenia, and thrombocytopenia 1–7 days postinfection 104 
(pi) (Fig. 1B–D). The titers of SFTSV in the organs (brains, lungs, livers, spleens, 105 
kidneys, and intestines) and plasma of infected Ifnar1
-/-
 and wild-type mice were also 106 
measured by focus forming assay at 3, 5, and 7 days pi. As shown in Fig. 2, efficient 107 
viral replication in Ifnar1
-/-
 mice was observed in the spleen and plasma at 3 days pi, all 108 
organs at 5 days pi, and the spleen, kidney, and intestine at 7 days pi. In contrast, we 109 
could not detect infectious SFTSV in the plasma or organs of wild-type mice. 110 
The results show that the SFTSV (YG-1) induces lethal acute infection 111 
accompanied by thrombocytopenia in Ifnar1
-/-




SFTSV causes lethal infection in Stat2
-/-
 mice, but not Stat1
-/-
 mice. 114 







 mice were infected with YG-1 strain. None of the infected Stat2-/- 116 
mice survived, while all of the Stat1
-/-
 mice infected with YG-1 survived (Fig. 1A). As 117 
shown in Fig. 1B, Stat2
-/-
 mice lost body weight at 1–7 days pi, while Stat1
-/-
 mice lost 118 
body weight at 1-5 days pi, and then recovered. Unlike in Ifnar1
-/-
 mice, the number of 119 




 mice transiently decreased after infection and 120 




 mice infected with 121 
SFTSV showed thrombocytopenia regardless of survival (Fig. 1D). This implies that the 122 
lethality of SFTSV is not associated with thrombocytopenia. Next, we measured the 123 
titers of SFTSV in organs (brains, lungs, livers, spleens, kidneys, and intestines) and 124 




mice by focus forming assay at 3, 5, and 7 days pi. 125 
In Stat2
-/- 
mice, SFTSV was detected in the plasma, spleen, and kidney at 3 days pi, the 126 
plasma and all organs at 5 days pi, and the spleen and kidney at 7 days pi. In Stat1
-/-
 127 
mice, SFTSV replicated in the lung, spleen, kidney, intestine, and plasma; however, the 128 
maximum titers of SFTSV in these organs and plasma were lower than those in Stat2
-/-
 129 
mice (Fig. 2). 130 
10 
 




 mice, but not Stat1
-/-
 mice, are 131 
highly susceptible to SFTSV infection, which suggests that STAT2 plays a critical role 132 
in the suppression of SFTSV replication in mice.  133 
 134 
SFTSV NSs cannot suppress type I IFN signaling in murine cells.  135 
It has been reported that SFTSV suppress type I IFN signaling in human cells (13). 136 
Therefore, we hypothesized that SFTSV cannot suppress type I IFN signaling in murine 137 
cells, and IFN-mediated innate immunity restricts SFTSV replication in mice. To 138 
address this possibility, the ISRE activation by SFTSV infection was examined in 139 
human-derived HEK293T cells and mouse-derived NIH3T3 cells using dual-luciferase 140 
reporter (DLR) gene assay. As shown in Fig 3A, SFTSV infection did not induce the 141 
ISRE activation in HEK293T cells, while the ISRE activation was induced by SFTSV 142 
infection in NIH3T3 cells. These results suggest that SFTSV cannot inhibit type I IFN 143 
signaling in murine cells. 144 
Recently, SFTSV NSs has been reported to function as an IFN antagonist (13-15)., 145 
Therefore, the effects of NSs on ISRE activation in HEK293T cells and NIH3T3 cells 146 
were examined by DLR gene assay. In this experiment, the VP40 protein of 147 
mouse-adapted Marburg virus (mMARV), which functions as an IFN signaling inhibitor 148 
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in murine cells, was used as a positive control (20). As shown in Fig. 3B, IFN-αA/D 149 
treatment induced strong ISRE activation in both HEK293T and NIH3T3 cells. As 150 
expected, the expression of SFTSV NSs significantly inhibited the ISRE activation 151 
driven by IFN-αA/D in HEK293T cells, while NSs expression did not suppress this 152 
activation in NIH3T3 cells (Fig. 3B). We also confirmed that the ISRE activation driven 153 
by IFN-αA/D in NIH3T3 cells was suppressed by the expression of mMARV VP40 (Fig. 154 
3C). These results suggest that SFTSV NSs cannot interfere with type I IFN signaling in 155 
murine cells. 156 
We also examined the effect of NSs on IFN-αA/D-induced expression of mRNA 157 
for two ISGs, ISG56 and oligoadenylate synthetase 1 (OAS1), by real-time qPCR. The 158 
induction of both ISGs by IFN in HEK293T cells was suppressed by NSs expression, 159 
whereas NSs did not suppress induction in NIH3T3 cells (Fig. 3D). 160 
 161 
NSs does not interact with murine and hamster STAT2.  162 
SFTSV NSs inhibits type I IFN signaling by the interaction with human STAT1 163 
(hSTAT1) and STAT2 (hSTAT2) (13-15). However, the interaction with hSTAT1 is 164 
weaker than that with hSTAT2 (15). We also showed here that mice deficient for STAT2, 165 
but not STAT1, were highly susceptible to SFTSV infection and progressed to severe 166 
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disease (Fig1). Therefore, we suggest that NSs cannot interact with murine STAT2 and 167 
thus cannot antagonize IFN signaling in murine cells. 168 
First, to examine whether NSs interacts with murine STAT2 (mSTAT2), we 169 
performed co-immunoprecipitation (co-IP) assays using lysates from cells transfected 170 
with a NSs expression plasmid. As shown in Fig. 4A, co-IP of STAT2 with NSs was 171 
observed only in the lysates from HEK293T cells, but not from NIH3T3 cells, 172 
suggesting that NSs interact with hSTAT2 but not with mSTAT2. It was also indicated 173 
that NSs bound to hSTAT1, but not to murine STAT1 (mSTAT1) (Fig. 4A).  174 
We also examined the interaction of NSs with hamster STAT2 (hamSTAT2) by 175 
co-IP assay, since Stat2
-/-
 hamsters, like Stat2
-/-
 mice, are highly susceptible to SFTSV 176 
infection (19). As shown in Fig. 4B, the interaction of NSs with hamSTAT2, as well as 177 
mSTAT2, was not observed.  178 
The interaction of NSs with STAT2 was also examined by subcellular 179 
colocalization of the proteins. The NSs expression plasmid was cotransfected with the 180 
expression plasmids for hSTAT2, mSTAT2, or hamSTAT2 into HEK293T, NIH3T3, or 181 
BHK-21 cells, respectively, and subcellular localizations of proteins were observed. 182 
Cytoplasmic inclusion bodies (IBs), mainly formed by NSs, were also observed in 183 
HEK293T, NIH3T3, and BHK-21 cells (Fig. 4C). In HEK293T cells, hSTAT2 184 
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colocalizes with NSs, consistent with previous reports (13-15). On the other hand, in 185 
NIH3T3 and BHK-21 cells, colocalization of NSs with mSTAT2 or hamSTAT2 was not 186 
observed (Fig. 4C). These findings indicate that NSs interacts with hSTAT2, but not 187 
mSTAT2 and hamSTAT2. 188 
  189 
The N-terminal region of hSTAT2 is important for binding to NSs. 190 
To investigate the difference in NSs binding between human and murine STAT2, 191 
we prepared a series of chimeric proteins from hSTAT2 and mSTAT2 (Fig. 5A). The 192 
interactions between NSs and the chimeric STAT2 proteins were examined by co-IP 193 
assay. All chimeric proteins efficiently expressed in NIH3T3 cells (Fig. 5B). As shown 194 
in Fig. 5B, NSs interacted with hSTAT2, HHM, HMM, H(101–315)MM, and H(101–195 
315)HM, but not mSTAT2, MHH, MMH, H(1–100)MM, H(1–221)MM and H(222–196 
315)MM. 197 
We also confirmed the results by observation of colocalization of the proteins (Fig. 198 
5C). NSs colocalized with hSTAT2, HHM, HMM, H(101–315)MM and H(101–199 
315)HM, while mSTAT2, MHH, MMH, H(1–100)MM, H(1–221)MM, and H(222–200 
315)MM, did not colocalize with NSs. These results are consistent with those from the 201 
co-IP assay. It has been reported that SFTSV NSs interacts with the DNA-binding 202 
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domain (DBD: amino acid position 316–485) of hSTAT2 (13). Taken together, these 203 
results suggest that region 101–315 of hSTAT2 is important for the binding to NSs in 204 
addition to the DBD, or that this region of mSTAT2 interferes with the binding to NSs.  205 
To further examine whether MHH and MMH, which cannot bind to NSs, function 206 
as STAT2 proteins in the presence of NSs, ISRE activation by MHH or MMH in the 207 
presence of NSs was investigated by the DLR assay in HEK293T cells. ISRE activation 208 
was reduced by NSs in the absence of exogenous STAT2, and overexpression of 209 
exogenous hSTAT2 slightly compensated for this reduction induced by NSs (Fig. 6). In 210 
contrast, the suppression of ISRE activation by NSs was significantly recovered by 211 
mSTAT2, MMH, and MHH, suggesting that MMH and MHH, as well as mSTAT2, 212 
activate ISRE as a functional STAT2 protein in the presence of NSs in HEK293T cells. 213 
 214 
Type I IFN induces the phosphorylation of mSTAT2 in the presence of NSs.  215 
Tyrosine phosphorylation of STAT2 is important for its function as a transcription 216 
factor in the type I IFN signaling pathway (21). To assess whether type I IFN signaling 217 
can phosphorylate mSTAT2 in the presence of NSs, HEK293T and NIH3T3 cells were 218 
transfected with empty vector or the NSs-HA expression plasmid, and then treated with 219 
IFN-A/D. The expression levels of hSTAT2 and mSTAT2 were stable regardless of 220 
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NSs expression (Fig. 7A). In the absence of NSs, IFN induced the phosphorylation of 221 
hSTAT2 and mSTAT2. hSTAT2 phosphorylation in HEK293T cells was significantly 222 
downregulated by NSs in a concentration-dependent manner. In contrast, mSTAT2 in 223 
NIH3T3 cells was phosphorylated irrespective of NSs expression (Fig. 7A). These were 224 
also observed in SFTSV infected cells (Fig. 7B). It is likely that NSs cannot interfere 225 
with the phosphorylation of mSTAT2, since NSs cannot bind to mSTAT2. 226 




Previous studies in animal models of SFTSV infection indicated the importance 229 
of the type I IFN response in mice and STAT2 in hamsters to prevent disease 230 
progression (16-17, 19). Both STAT1 and STAT2 have been found to be key factors in 231 
the IFN signaling pathway (21). In this study, we demonstrated that STAT2-deficient 232 
mice, as well as type I IFN receptor-deficient mice, are more susceptible to SFTSV than 233 
STAT1-deficient mice and wild-type mice. Moreover, our results indicate that NSs has 234 
no ability to suppress the IFN signaling pathway in murine cells because NSs, which 235 
binds hSTAT1 and hSTAT2, cannot interact with mSTAT1 and mSTAT2. The SFTSV 236 
growth in the organs of Stat1
-/-
 mice were much less efficient than those in Stat2
-/-
 and 237 
Ifnar1
-/-
 mice, although SFTSV could grow in Stat1
-/-
 mice (Fig. 2). In addition, SFTSV 238 
infection induced milder symptom in Stat1
-/-




 mice (Fig. 239 
1). These suggests that innate immunity dependent on STAT2, but not STAT1, strongly 240 
inhibits the replication of SFTSV in mice. In several human cell lines, the expression of 241 
some ISGs is upregulated by STAT2, independent of STAT1 (22). For example, the 242 
expression levels of several ISGs including APOBEC3G, PKR, ISG15, and Mx1 are 243 
increased by type I IFN stimulation regardless of STAT1 expression in the human liver 244 
cell lines, Huh7 and Hep3B. However, when the expression of STAT2 is suppressed, the 245 
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expression levels of these ISGs are not increased after type I IFN treatment. These 246 
findings suggest that ISGs expression mediated by STAT2, but not STAT1, suppress 247 
mainly SFTSV infection in mice.  248 
 SFTSV causes severe disease in human, while immunocompetent adult mice 249 
never show any apparent severe symptoms after SFTSV infection (18). In this study, we 250 
showed that mice lacking STAT2 are highly susceptible to SFTSV infection. Moreover, 251 
NSs can suppress the phosphorylation of hSTAT2, whereas the phosphorylation of 252 
mSTAT2 is not inhibited by NSs due to the inability of NSs to bind to mSTAT2. The 253 
data also indicates that NSs cannot interact with hamSTAT2. This result is consistent 254 
with a previous report showed that STAT2-deficient hamsters are also highly susceptible 255 
to SFTSV infection (19). 256 
The relationship between NSs and STAT2 is reminiscent of that of dengue virus 257 
NS5 and STAT2 (A23-25). Previous studies reported that innate immunity mediated by 258 
mSTAT2 restricts dengue virus replication in mice (25-26). To block the type I IFN 259 
signaling pathway in humans, dengue virus NS5 expression leads to the degradation of 260 
hSTAT2 (25). However, NS5 cannot suppress type I IFN signaling in mice, because 261 
mSTAT2 is resistance to NS5-mediated degradation (23-25). These results demonstrate 262 
that STAT2 may be one of the determinants for the species specificity of dengue virus. 263 
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Here, we elucidated that SFTSV induces lethal disease in STAT2-deficient mice and that 264 
NSs cannot interact with mSTAT2. Thus, similar to dengue virus NS5, the anti-STAT2 265 
activity of NSs appears to determine the species specificity of SFTSV infection. 266 
In this study, chimeric mutants of hSTAT2 and mSTAT2 revealed that residues 267 
101–315 of hSTAT2 are required for the interaction with NSs or that these residues in 268 
mSTAT2 interfere with the interaction with NSs. We also confirmed that mSTAT2 and 269 
all of the chimeric mutants of hSTAT2 and mSTAT2 used in this study can activate 270 
ISRE-mediated gene expression as functional STAT2 proteins. Previously, Ning et al. 271 
reported that the DBD region (316–485) of hSTAT2 is required for the interaction with 272 
NSs (13). However, we showed that mutants possessing the DBD region of mSTAT2, 273 
HMM, and H(101–315)MM, can still bind to NSs (Fig. 5). At present, we cannot 274 
explain this result, although this discrepancy may be explained by the differences in the 275 
three-dimensional protein structure between our mutants and Ning’s deletion mutants. 276 
Further analyses will be required to clarify this issue. 277 
Taken together, we conclude that the anti-STAT2 activity of NSs determines the 278 
species specificity of SFTSV infection. In addition, we show that Stat2
-/-
 mice, as well 279 
as Ifnar1
-/-
 mice and Stat2
-/-
 hamsters, are highly susceptible to SFTSV infection, which 280 
causes lethal disease, suggesting that Stat2
-/-
 mice may be useful as an animal model to 281 
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develop antiviral drugs against SFTSV infection. 282 
  283 
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MATERIALS AND METHODS 284 
Ethics statement. 285 
Our research protocol for the use of mice follows the Nagasaki University Regulations 286 
for Animal Care and Use, which was approved by the Animal Experiment Committee of 287 
Nagasaki University (approval number; 151110-1-5). 288 
 289 
Animals. 290 





) (27) was provided by RIKEN BRC through the National BioResource 292 
Project of MEXT, Japan. Ifnar1
–/–







 mice were provided by Dr. Takayuki Yoshimoto (Tokyo Medical 294 
University). Stat2
-/-
 mice were purchased from the Jackson Laboratory. The genetical 295 
backgrounds of all mice used in this study are C57BL/6.  296 
 297 
SFTSV infection in mice. 298 
Six- to eight-week-old male or female mice were used in this study. In infection 299 
experiments, each mouse was infected with SFTSV by intradermal injection (50 μL of 300 
virus solution for 10 FFU). Mouse survival and body weight changes were monitored 301 
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daily for 14 days pi. At 1, 3, and 7 days pi, blood was collected, and platelets and 302 
leukocytes were counted using a hematology analyzer (Sysmex pocH-100iV; Sysmex or 303 
VetScan HMII; Abaxis). Mice were euthanized, and plasma and organs (lungs, livers, 304 
spleens, kidneys, intestines, and brains) were collected. Viruses in plasma were titrated 305 
by focus forming assay using Vero E6 cells. To determine the titer of SFTSV in organs, 306 
mouse organs were collected in a 9-fold volume of minimum essential media 307 
(Sigma-Aldrich) and then disrupted through high-speed shaking using TissueLyser II 308 
(Qiagen). After centrifugation (700 x g, 5min, 4°C), the amounts of viruses in the 309 
homogenates (10% w/v) were determined by focus forming assay in VeroE6 cells. The 310 
limit of detection is 100FFU/g. 311 
 312 
Cell culture and virus. 313 
Human embryonic kidney (HEK) 293T (CRL-11268; ATCC), NIH3T3 (CRL-1658; 314 
ATCC), BHK-21 (JCRB9020; Health Science Research Resources Bank (HSRRB)), 315 
and Vero E6 (CRL-1586; ATCC) cells were cultured in Dulbecco modified Eagle 316 
medium (Sigma-Aldrich) supplemented with 10% heat-inactivated (fetal calf serum) 317 
FCS and antibiotics (Thermo Fisher Scientific). The SFTSV (YG1), a field isolate from 318 
an SFTS patient in Japan, was kindly provided by Dr. Ken Maeda, Yamaguchi 319 
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University (28). The virus stocks were prepared from culture supernatants of Vero E6 320 
cells. 321 
 322 
Focus forming assay. 323 
SFTSV titers were determined using a focus forming assay. Briefly, confluent 324 
monolayers of Vero E6 cells were inoculated with 10-fold dilutions of SFTSV and 325 
incubated at 37°C for 1 hour. The inoculum was removed, and cells were washed and 326 
overlaid with MEM (Sigma-Aldrich) containing 0.7% agarose and 0.7% FCS. After 4 327 
days, cells were fixed with 4% paraformaldehyde and permeabilized with 328 
phosphate-buffered saline (PBS) containing 1% Triton X-100. Cells were blocked with 329 
PBS containing 0.1% Triton X-100 and 1% bovine serum albumin (BSA), and then 330 
incubated with anti-SFTSV N protein rabbit polyclonal antibody (28). After washing 331 
with PBS, the cells were incubated with anti-rabbit IgG conjugated with horseradish 332 
peroxidase (Promega). After more washes with PBS, SFTSV-infected cells were 333 
detected by using Peroxidase Stain DAB Kit and Metal Enhancer for DAB Stain 334 
(Nacalai Tesque). The number of SFTSV N positive cells were determined and 335 





The open reading frame (ORF) encoding NSs was amplified by reverse transcription 339 
PCR (RT-PCR) from SFTSV (YG-1) viral RNA and inserted into pcDNA3.1 340 
(Invitrogen) with a hemagglutinin (HA) tag using the primers listed in Table 1 to 341 
produce pcDNA3.1/NSs-HA. To prepare the expression plasmids for 6xHistidine 342 
(His)-tagged hSTAT2 (pcDNA3.1/hSTAT2-His), mSTAT2 (pcDNA3.1/mSTAT2-His), 343 
and hamSTAT2 (pcDNA3.1/hamSTAT2-His), the desired genes were amplified by 344 
RT-PCR using the primers listed in Table 1 from the cDNA of HEK293T, NIH3T3, and 345 
BHK-21 cells, respectively. The expression plasmids for the series of STAT2 chimeras 346 
were constructed using an In-Fusion HD Cloning kit (TaKaRa) with the primers listed 347 
in Table 1. The expression plasmid for mMARV VP40 was constructed from MARV 348 
VP40 (28) using a KOD-Plus-Mutagenesis Kit (TOYOBO) using the primers listed in 349 
Table 1. 350 
 351 
Reporter gene assay.  352 
HEK293T cells and NIH3T3 cells were cotransfected with ISRE reporter plasmid (450 353 
ng) (Promega) and pRL-TK plasmid [the Renilla luciferase control plasmid for the 354 
constitutively active herpes simplex virus (HSV)-thymidine kinase (TK) promoter] (100 355 
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ng) (Promega). Twenty-four hours after transfection, the transfected cells were 356 
mock-infected or infected with SFTSV. Two days after infection, luciferase activities 357 
were measured with a DLR assay kit (Promega) and a TriStar LB941 system (Berthold).  358 
For the reporter gene assays with SFTSV NSs transfection, the ISRE reporter plasmid 359 
(500 ng) (Promega) and pRL-TK [the Renilla luciferase control plasmid for the 360 
constitutively active herpes simplex virus (HSV)-thymidine kinase (TK) promoter] 361 
plasmid (100 ng) (Promega) were transfected into HEK293T and NIH3T3 cells with or 362 
without the indicated amount of pcDNA3.1/NSs-HA plasmid or the expression plasmid 363 
for mMARV VP40 (800 ng) using LT-1 (Mirus) or Lipofectamine 3000 (Thermo Fisher 364 
Scientific) according to the manufacturer’s instructions. Twenty-four hours after 365 
transfection, cells were treated with IFN-A/D (500 U/ml) (Sigma-Aldrich) or were left 366 
untreated for 18 h. Luciferase activities then were measured with a DLR assay kit 367 
(Promega) and a TriStar LB941 system (Berthold).  368 
 369 
Quantitative real-time reverse transcription PCR (RT-PCR) of IFN-treated cells.  370 
Total RNA was extracted from HEK293T and NIH3T3 cells using an RNeasy Mini kit 371 
(Qiagen). Real-time RT-PCR was performed by using the One Step TB Green™ 372 
PrimeScript™ PLUS RT-PCR Kit (TaKaRa) according to the manufacturer's 373 
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instructions, and the PCR primers used in this study are listed in Table 1. Relative 374 
mRNA levels were calculated by the 2
-ΔΔCT
 method with GAPDH mRNA as an internal 375 
control and are shown as relative fold changes normalized to the untreated control 376 
samples. 377 
 378 
Immunoblotting.  379 
Protein samples were separated by SDS-PAGE and transferred to nitrocellulose 380 
membranes (Millipore). After blocking with 5% skim milk in Tris-buffered 381 
saline/Tween 20 (TBS-T), the membranes were incubated with each of the following 382 
antibodies: anti-HA (18850; QED Biosciences Inc.), anti-His (9F2; Wako), anti-hSTAT2 383 
(A-9; Santa Cruz), anti-mSTAT2 (07-140; Merc), anti-STAT2 (phosphor Y690) 384 
(ab53132; Abcam), anti-STAT1 (D19KY; Cell signaling) or anti-actin (AC-15; 385 
Sigma-Aldrich). After washing with TBS-T, the membranes were incubated with 386 
horseradish peroxidase-labeled secondary antibodies, Anti-Mouse IgG-HRP (A2304; 387 
Sigma-Aldrich) or Anti-Rabbit IgG-HRP (WA4011; Promega), and then detected using 388 
ECL prime (GE Healthcare) according to the manufacturer’s instructions. Bands were 389 




Co-IP assay.  392 
To examine the binding of NSs to endogenous STAT2, the pcDNA3.1/NSs-HA plasmid 393 
(15 μg) was transfected into HEK293T and NIH3T3 cells in 10-cm dishes (Thermo 394 
Fisher Scientific) using LT-1 or Lipofectamine 3000, respectively. To examine the 395 
binding of NSs to exogenous STAT2 or STAT2 derivatives, the pcDNA3.1/NSs-HA 396 
plasmid (3 μg) was cotransfected into NIH3T3 cells with each STAT2 expression 397 
plasmid (1 μg) in 6-well plates (Thermo Fisher Scientific) using Lipofectamine 3000. 398 
Two days after transfection, cells were lysed in lysis buffer (25 mM Tris-HCl, 150 mM 399 
NaCl, 1 mM EDTA, and 1% Triton X-100) containing a protease inhibitor cocktail 400 
(Roche). To perform the co-IP assay, cell lysates were mixed with magnetic beads 401 
conjugated to an anti-His monoclonal antibody (OGHis; MBL) or anti-HA monoclonal 402 
antibody (5D8; MBL) and incubated at 4°C for 3 h or overnight, respectively. Then, the 403 
magnetic beads were washed with lysis buffer and wash buffer (50 mM Tris-HCl, 1% 404 
NP-40, 0.25% deoxycholic acid sodium salt, 150 mM NaCl, and 1 mM EDTA) and 405 
analyzed by immunoblotting as described above. 406 
 407 
Immunofluorescence assay (IFA).  408 
The expression plasmids for His-tagged hSTAT2, mSTAT2, hamSTAT2, or a series of 409 
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STAT2 chimeras were cotransfected into HEK293T, NIH3T3, or BHK-21 cells with the 410 
pcDNA3.1/NSs-HA plasmid. Twenty-four hours after transfection, transfected cells 411 
were fixed using 4% paraformaldehyde-PBS (Wako), and then the fixed cells were 412 
incubated in 1% Triton X-100 in PBS for permeabilization and blocked in 10% FCS in 413 
blocking buffer (3% BSA and 0.3% Triton X-100 in PBS). Cells then were treated with 414 
primary antibodies (anti-HA (18850; QED Biosciences Inc.) or anti-His (9F2; Wako)) 415 
overnight at 4°C and stained with secondary antibodies (Anti-Rabbit IgG - H&L (FITC) 416 
(ab6009; abcam) or Anti-Mouse IgG (whole molecule) −TRITC (T5393; 417 
Sigma-Aldrich)) for 2 h at room temperature with DAPI (Roche) for visualization of 418 
nuclei. Image acquisition was performed with a LSM780 microscope (Carl Zeiss) 419 
 420 
Statistical analyses. Significant differences in virus titers in mouse organs among 421 
mouse strains were determined by one-way ANOVA following Tukey’s multiple 422 
comparisons test using GraphPad Prism software. And statistically significant 423 
differences in the data of Fig3A, 3B, 3C, 3D and 6 were determined using Student's 424 
t-test (Fig3A. 3C and 3D) or Dunnett's test (Fig 3B and 6). 425 
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FIGURE LEGENDS 555 







 mice were infected with 10 FFU of SFTSV (YG1). (A) 557 
Survival and (B) body weight changes were observed daily for 14 days pi (n = 10). For 558 
WBC and PLT counts, blood samples were collected from two male and three female 559 
mice at 0, 1, 3, 5, and 7 days pi. The values are shown as mean ± Standard Divisions 560 
(SDs). 561 
 562 
Fig. 2. Titers of SFTSV in mouse organs. Mice were inoculated with 10 FFU of SFTSV 563 
YG1. Three female mice were euthanized for virus titration at 3, 5, and 7 days pi. The 564 
virus titers in the mouse brains, lungs, livers, spleens, kidneys, intestines, and plasma 565 
were measured by focus forming assay. The values are shown as mean ± SDs (n = 3). 566 
*P < 0.05, compared among each mouse strain. 567 
 568 
Fig. 3. The function of NSs as an IFN antagonist in human and murine cells. (A) HEK 569 
293T or NIH3T3 cells transfected with the reporter plasmids were mock-infected or 570 
infected with SFTSV. Two days after infection, cells were lysed to measure luciferase 571 
activity and to examine the protein expression using immunoblotting. Relative light 572 
units (RLU) in mock-infected cells were set as 1. Fold activation by SFTSV infection 573 
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are indicated. (B) The reporter plasmids were transfected into HEK293T or NIH3T3 574 
cells with or without the expression plasmid for NSs. Twenty-four hours after 575 
transfection, cells were treated with or without IFN-A/D (500 U/ml) for 18 hours and 576 
then were lysed to measure luciferase activity and detect protein expression using 577 
immunoblotting. RLU in cells transfected with the empty vector or the indicated amount 578 
of NSs expression plasmid in the absence of IFN-A/D were set as 1. Fold activation by 579 
IFN-A/D are indicated. (C) The experiment done in (B) was repeated using the 580 
expression plasmid for mMARV VP40 in NIH3T3 cells. (D) NSs expression plasmid (1 581 
μg or 1.5μg) or control plasmid was transfected into HEK293T or NIH3T3 cells, 582 
respectively. Twenty-four hours after transfection, the cells were treated with IFN-A/D 583 
(200 U/ml) or left untreated for 10 hours. Expression levels of Isg56 and Oas1 mRNAs 584 
in each cell line were measured by real-time qPCR. The mRNA expression levels of 585 
ISG56 and OAS1 in IFN-A/D untreated cells were set as 1. Fold activations by 586 
IFN-A/D are indicated. These assays were independently performed in triplicate. The 587 
data represent averages with SDs. **in panel A and B, P < 0.05 versus no NSs. 588 
 589 
Fig. 4. Interaction of NSs with STAT1 and STAT2. (A) HEK293T or NIH3T3 cells were 590 
transfected with the expression plasmid for HA-tagged NSs and co-IP assays were 591 
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performed. (B) NIH3T3 cells were transfected with the expression plasmids for 592 
HA-tagged NSs and His-tagged hSTAT2 or hamSTAT2. The protein expression levels in 593 
cell lysates (left) and in co-IP assays (right) using an anti-HA or anti-His antibody. (C) 594 
Colocalization of NSs with STAT2. HEK293T, NIH3T3, or BHK-21 cells were 595 
transfected with the expression plasmid for HA-tagged NSs and the expression plasmid 596 
for His-tagged hSTAT2, mSTAT2, or hamSTAT2, respectively. IFA was also performed 597 
with NSs, STAT2, and the nuclei shown in green, red, and blue, respectively. 598 
 599 
Fig. 5. Determination of the region of hSTAT2 important for the binding to NSs. (A) 600 
Schematic representation of the chimeric mutants of hSTAT2 and mSTAT2. (B) 601 
NIH3T3 cells were cotransfected with the expression plasmids for HA-tagged NSs and 602 
each of the STAT2 His-tagged chimeras. Representative results from the protein 603 
expression check in cell lysates (upper) and the co-IP assays using an anti-His antibody 604 
(lower) are shown. (C) IFA was also performed with NSs, STAT2, and the nuclei shown 605 
in green, red, and blue, respectively. 606 
 607 
Fig. 6. Function of the NSs binding-deficient STAT2 chimera. The reporter plasmids 608 
were cotransfected into HEK293T cells with the expression plasmids for NSs and each 609 
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STAT2 chimera. Twenty-four hours after transfection, cells were treated with or without 610 
IFN-A/D (500 U/ml) for 18 hours and then were lysed to measure luciferase activity 611 
(upper figure) or detect protein expression using immunoblotting (lower figure). The 612 
ISRE activity was calculated by dividing RLU in IFN-A/D-treated cells by the units 613 
IFN-A/D untreated cells. The ISRE activity in the absence of NSs was set as 100%. 614 
The assays were independently performed in triplicate. The data represent averages with 615 
SDs. ** P < 0.05 versus hSTAT2. 616 
 617 
Fig. 7. Suppression of STAT2 phosphorylation by NSs. (A) HEK293T or NIH3T3 cells 618 
transfected with the expression plasmid for HA-tagged NSs were treated with 619 
IFN-A/D (2000 U/ml) or left untreated for 45 minutes and were then lysed for 620 
detection of each protein expression by immunoblotting. (B) HEK293T or NIH3T3 cells 621 
infected with SFTSV at an MOI of 10 were treated with IFN-A/D (2000 U/ml) or left 622 
untreated for 45 minutes and were then lysed for detection of each protein expression by 623 
immunoblotting. 624 
  625 
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Table 1. List of the primers used in this study









































For the construction of
pcDNA3.1/NSs-HA
For the construction of
pcDNA3.1/hSTAT2-His
For the construction of
pcDNA3.1/mSTAT2-His
For the construction of
pcDNA3.1/hamSTAT2-His
For the construction of
pHHM(#1)
For the construction of
pHMM(#2)
For the construction of
pMHH(#3)
For the construction of
pMMH(#4)
For the construction of
pH(1-100)MM(#5)




















MARV VP40 S15PF cttgaacccccctccttatgctgatcacgg
MARV VP40 S15PR tattgcatgtatgtgttgtaattgctggaactggcc
MARV VP40 G79SF gttccggcatggctgcctcttgg













For the Real-time RT-PCR
detection of human GAPDH
For the Real-time RT-PCR
detection of mouse GAPDH
(Ref: 32)
For the construction of
pH(101-315)HM(#9)
For the construction of
pmMARV VP40
For the Real-time RT-PCR
detection of human ISG56
(Ref: 13)
For the Real-time RT-PCR
detection of mouse ISG56
(Ref: 30)
For the Real-time RT-PCR
detection of human OAS1
(Ref: 13)
For the Real-time RT-PCR
detection of mouse OAS1
(Ref: 31)
For the construction of
pH(101-315)MM(#8)
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